Combination therapy using cancer vaccine, antigen-specific CTL and an anticancer drug for renal cell carcinoma

• Project/Area Number: 24592415
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Aichi Medical University
• Principal Investigator: Yoshikawa Kazuhiro 愛知医科大学, 医学部, 教授 (60109759)
• Research Collaborator: SUZUKI Susumu ; KASHIWAGI Takahiro ; NISHIO Mayako ; NISHINO Tokiko
• Project Period (FY): 2012-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 免疫治療 / 細胞治療 / 併用療法 / 抗がん剤 / CTL / 細胞療法 / 免疫療法 / ワクチン

Outline of Final Research Achievements

In this study, we tried to improve immune-cell therapy for cancer by improvement of an amplification system of cytotoxic T-cells (CTL) activated with cancer peptide vaccine and, combination with CTL and anticancer drugs.
CTLs were able to induce and expand in efficiently using cancer peptide vaccine as activation antigen. The influence of anticancer drugs for CTLs were tested using CTLs activated with a CMV peptide. Docetaxel, Gemcitabin and Cisplatin did not show any influence for reactivity of CTL, but showed inhibition activity for proliferation. These results showed that Docetaxel, Gemcitabin and Cisplatin were able to use with CTLs for treatment with cancer patients, but not combination with peptide vaccines. Iressa, Sorafenib and 5-FU did not show any influence for reactive activity and proliferation of CTL, and direct cytotoxicity for CTLs. These results indicate that these drugs can be used with CTLs and peptide vaccines for the treatment of cancer patients.

Research Products

• [Journal Article] Current status of immunotherapy. (2016)
  • Author(s): Suzuki S, Ishida T, Yoshikawa K and Ueda R.
  • Journal Title: Jpn J Clin Oncol Volume: 46 Issue: 3 Pages: 191-203
  • DOI: 10.1093/jjco/hyv201
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers. (2014)
  • Author(s): Ohtani T, Yamada Y, Furuhashi A, Ohmura Y, Nakamura S, Kato H, Yoshikawa K, Kazaoka Y
  • Journal Title: Int J Oncol. Volume: 45 Issue: 5 Pages: 2051-2057
  • DOI: 10.3892/ijo.2014.2599
  • Peer Reviewed
• [Journal Article] The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer (2014)
  • Author(s): Sugimoto Y, Hirota M, Yoshikawa K, Sumitomo M, Nakamura K, Ueda R, Niwa R, Suzawa T, Yamasaki M, Shitara K, Kato T, Nakamura K.
  • Journal Title: Anticancer Res. Volume: 34 Pages: 89-97
  • Peer Reviewed
• [Journal Article] Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts (2013)
  • Author(s): Shimazui T, Yoshikawa K, Miyazaki J, Kojima T, Inai H, Ando S, Uemura H, Uchida K, Nishiyama H
  • Journal Title: Int. J. Oncol Volume: Vo l .42 Issue: 2 Pages: 543-54
  • DOI: 10.3892/ijo.2012.1752
  • Peer Reviewed
• [Presentation] Clinical application of anti-CCR4 monoclonal antibody (2014)
  • Author(s): Ryuzo Ueda, Susumu Suzuki, Kazuhiro Yoshikawa, Takashi Ishida
  • Organizer: The 45th International Symposium of the PrincessTakamatsu Cancer Research Fund
  • Place of Presentation: パレスホテル東京
  • Year and Date: 2014-11-18 – 2014-11-20
  • Invited
• [Presentation] 頭頸部扁平上皮癌(HNSCC)における5-フルオロウラシル(5-FU)併用免疫療法 (2014)
  • Author(s): 西尾麻矢子、鈴木進、大村元伸、山田陽一、上田龍三、吉川和宏、風岡宜暁
  • Organizer: 第７３回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2014-09-25 – 2014-09-27
• [Presentation] Development of CTL preparation kit for adoptive T cell Immunotherap (2012)
  • Author(s): Suzuki S, Yoshikawa K, Takahashi Y, Kojima S, Ueda R
  • Organizer: 20th Annual Cancer Research Institutte International Symposium “Cancer Immunotherapy 2012”
  • Place of Presentation: New York
• [Book] Inflammation and Immunity in Cancer (2015)
  • Author(s): Suzuki S, Ishida T, Yoshikawa K, Ueda R
  • Total Pages: 268
  • Publisher: Springer
• [Book] Inflammation and Immunity in Cancer (2015)
  • Author(s): Susumu Suzuki, Takashi Ishida, Kazuhiro Yoshikawa, Ryuzo Ueda
  • Total Pages: 268
  • Publisher: Springer